543828

Sudarshan Pharma Industries Share Price

 

 

Start SIP in 543828

Start SIP

Performance

  • Low
  • ₹23
  • High
  • ₹24
  • 52 Week Low
  • ₹22
  • 52 Week High
  • ₹45
  • Open Price₹24
  • Previous Close₹23
  • Volume124,000
  • 50 DMA₹25.51
  • 100 DMA₹26.62
  • 200 DMA₹27.82

Investment Returns

  • Over 1 Month -7.67%
  • Over 3 Month -13.33%
  • Over 6 Month -20.47%
  • Over 1 Year -50.21%

Smart Investing Starts Here Start SIP with Sudarshan Pharma Industries for Steady Growth!

Invest Now

Sudarshan Pharma Industries Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 34.5
  • PEG Ratio
  • -
  • Market Cap Cr
  • 551
  • P/B Ratio
  • 3.9
  • Average True Range
  • 1.72
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.19
  • RSI
  • 37.84
  • MFI
  • 49.91

Sudarshan Pharma Industries Financials

Sudarshan Pharma Industries Technicals

EMA & SMA

Current Price
₹22.88
-0.22 (-0.95%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹24.79
  • 50 Day
  • ₹25.51
  • 100 Day
  • ₹26.62
  • 200 Day
  • ₹27.82

Resistance and Support

23.07 Pivot Speed
  • R3 24.97
  • R2 24.46
  • R1 23.58
  • S1 22.19
  • S2 21.68
  • S3 20.80

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sudarshan Pharma Industries has an operating revenue of Rs. 591.39 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 4% needs improvement, ROE of 12% is good. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 86 which is a GOOD score indicating consistency in earnings, a RS Rating of 23 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 72 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of D is close to being the worst. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sudarshan Pharma Industries Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-10-18 Half Yearly Results
2025-08-14 Quarterly Results
2025-06-19 Others Inter-alia, to consider 1. Proposal for Raising further funds by way of issuance of equity shares or any other equity linked instruments, warrants, etc subject to applicable approvals. per share(3%)Final Dividend
2025-04-24 Audited Results
2025-01-10 To consider issue of Warrants
Date Purpose Remarks
2024-11-23 Split Rs.0.00 split from Rs. 10/- to Re. 1/-.

Sudarshan Pharma Industries F&O

Sudarshan Pharma Industries Shareholding Pattern

57.39%
19.78%
16.88%
5.95%

About Sudarshan Pharma Industries

  • NSE Symbol
  • 543828
  • BSE Symbol
  • 543828
  • Chairman & Managing Director
  • Mr. Hemal Vasantrai Mehta
  • ISIN
  • INE00TV01023

Similar Stocks to Sudarshan Pharma Industries

Sudarshan Pharma Industries FAQs

Sudarshan Pharma Industries share price is ₹22 As on 17 January, 2026 | 02:24

The Market Cap of Sudarshan Pharma Industries is ₹550.6 Cr As on 17 January, 2026 | 02:24

The P/E ratio of Sudarshan Pharma Industries is 34.5 As on 17 January, 2026 | 02:24

The PB ratio of Sudarshan Pharma Industries is 3.9 As on 17 January, 2026 | 02:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23